ESRRA and cancer: Noteworthily, recent studies also suggest that the CHOL-mediated ERRα activation can cause metabolic switching, leading to the propagation of cancer stem-like cells (CSCs) [32], triggering the epithelium–mesenchymal transition (EMT), the release of pro-inflammatory factors that can modify the tumor microenvironment [31], and the onset of drug resistance [33], as supported by the reduced ERRα transactivation observed after the treatment with statins [27].